CA2256015C - Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic - Google Patents
Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic Download PDFInfo
- Publication number
- CA2256015C CA2256015C CA002256015A CA2256015A CA2256015C CA 2256015 C CA2256015 C CA 2256015C CA 002256015 A CA002256015 A CA 002256015A CA 2256015 A CA2256015 A CA 2256015A CA 2256015 C CA2256015 C CA 2256015C
- Authority
- CA
- Canada
- Prior art keywords
- ang
- weak
- medium
- crystal modification
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- POGQSBRIGCQNEG-UHFFFAOYSA-N NC(c1c[n](Cc(c(F)ccc2)c2F)nn1)=O Chemical compound NC(c1c[n](Cc(c(F)ccc2)c2F)nn1)=O POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Abstract
The invention relates to the novel modifications B and C of the compound 1- (2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy and pharmaceutical preparations comprising these crystal modifications.
Description
CRYSTAL MODIFICATION OF I-(2,6-DIFLUOROBENZYL)-IH-1,2,3-TRIAZOLE-4-CARBOXAMIDE
AND ITS USE
AS ANTIEPILEPTIC
Background of the invention The compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the formula O
N
F NN
&F
is described in the European Patent Application with the Publication No. 0 199 (EP 199262), for example in Exampie 4. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic. The compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxylic acid, the procedure being analogous to Example 2.
EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to Example 4 is used in conjunction with Example 2, the crude 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted. It has now surprisingly been found that the different crystai modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization.
AND ITS USE
AS ANTIEPILEPTIC
Background of the invention The compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the formula O
N
F NN
&F
is described in the European Patent Application with the Publication No. 0 199 (EP 199262), for example in Exampie 4. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic. The compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxylic acid, the procedure being analogous to Example 2.
EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to Example 4 is used in conjunction with Example 2, the crude 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted. It has now surprisingly been found that the different crystai modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization.
-2-Descrigtion of the invention 1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be obtained in the novel crystal modifications A, A', B and C. These crystal modifications differ with respect to their thermodynamic stability, in their physical parameters, such as the absorption pattem of IR
and Raman spectra, in X-ray structure investigations and in their preparation processes.
The invention reiates to the novel crystal modifications B and C, their preparation and use in pharmaceutical preparations comprising this crystal modification.
The modification A', compared with A, has defects in the crystal lattice.
These are detectable, for example, by X-ray analysis, e.g. by smaller line spacings with otherwise predominantly identical lines or bands.
The crystal modification A of_ 1-(2,6-diffuorobenzy!)-1 H-1,2,3-triazole-4-carboxamide melts at 242 C (239-245 C).
In the FT infrared (FT-IR) spectrum (KBr pellet - transmission method), modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm" and 3092 cm"
[cf. Figure 1], which are not present in the FT-IR spectra of the modifications B and C.
In the range 4000-600 cm-', inter alia the following bands are obtained for modification A:
3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, TM
799, 781, 723, 688 and 640 cm''. For example, the apparatus IFS 88 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180 ), the modification A
or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularty characteristic are the band at 1080 cm'' [cf. Figure 2], which is not present in the Raman spectra of the modifications B and C. In the range 3400-300 cm'',
and Raman spectra, in X-ray structure investigations and in their preparation processes.
The invention reiates to the novel crystal modifications B and C, their preparation and use in pharmaceutical preparations comprising this crystal modification.
The modification A', compared with A, has defects in the crystal lattice.
These are detectable, for example, by X-ray analysis, e.g. by smaller line spacings with otherwise predominantly identical lines or bands.
The crystal modification A of_ 1-(2,6-diffuorobenzy!)-1 H-1,2,3-triazole-4-carboxamide melts at 242 C (239-245 C).
In the FT infrared (FT-IR) spectrum (KBr pellet - transmission method), modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm" and 3092 cm"
[cf. Figure 1], which are not present in the FT-IR spectra of the modifications B and C.
In the range 4000-600 cm-', inter alia the following bands are obtained for modification A:
3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, TM
799, 781, 723, 688 and 640 cm''. For example, the apparatus IFS 88 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180 ), the modification A
or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularty characteristic are the band at 1080 cm'' [cf. Figure 2], which is not present in the Raman spectra of the modifications B and C. In the range 3400-300 cm'',
-3-inter alia the following bands are obtained for the modification A: 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm''. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
The modification A has an X-ray powder pattem with characteristic lines with interplanar spacings (d values) of 10.5 A, 5.14 A, 4.84 A, 4.55 A, 4.34 A, 4.07 A, 3.51 A, 3.48 A, 3.25 A, 3.19 A, 3.15 A, 3.07 A, 2.81 A[cf. Table 1]. The measurement can be carried out, for example, in transmission geometry on an FR 552 Guinier camera from Enraf-Nonius, Delft (The Netherlands), using copper Ka, radiation (wavelength.%= 1.54060 A). The patterns recorded on X-ray film were measured using an LS-1 8 line scanner from Johannsson, Taby (Sweden) and evaluated using the Scanpi software (P.E.Wemer, University of Stockholm).
Characteristic for the modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230 C to 260 C. The peak temperature is 239-245 C, and the endothermic signal is 209 J/g +/- 10 J/g. The measurement was carried out TM
on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute.
The typical sample quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.
Crystals of the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattem in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 A and 3.64 A, 3.51 A and 3.48 A, 3.19 A and 3.15 A.
In the FT-IR spectrum (KBr pellet - transmission method), the novel modification B differs from the modification A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 1678 cm' [cf. Figure 1 ], which is not to be observed in the corresponding spectra of the modifications A and C. In the range
The modification A has an X-ray powder pattem with characteristic lines with interplanar spacings (d values) of 10.5 A, 5.14 A, 4.84 A, 4.55 A, 4.34 A, 4.07 A, 3.51 A, 3.48 A, 3.25 A, 3.19 A, 3.15 A, 3.07 A, 2.81 A[cf. Table 1]. The measurement can be carried out, for example, in transmission geometry on an FR 552 Guinier camera from Enraf-Nonius, Delft (The Netherlands), using copper Ka, radiation (wavelength.%= 1.54060 A). The patterns recorded on X-ray film were measured using an LS-1 8 line scanner from Johannsson, Taby (Sweden) and evaluated using the Scanpi software (P.E.Wemer, University of Stockholm).
Characteristic for the modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230 C to 260 C. The peak temperature is 239-245 C, and the endothermic signal is 209 J/g +/- 10 J/g. The measurement was carried out TM
on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute.
The typical sample quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.
Crystals of the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattem in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 A and 3.64 A, 3.51 A and 3.48 A, 3.19 A and 3.15 A.
In the FT-IR spectrum (KBr pellet - transmission method), the novel modification B differs from the modification A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 1678 cm' [cf. Figure 1 ], which is not to be observed in the corresponding spectra of the modifications A and C. In the range
-4- _ 4000-600 cm", inter alia the following bands are obtained for the modification B: 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm". For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180 ), the novel modification B
differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm"
and 1086 cm" [cf. Figure 2], which are not present in the Raman spectra of the modifications A and C. In the range 3400-300 cm-', inter alia the following bands are obtained for the modification B: 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm''. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
The novel modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A, 2.83 A [cf. Table 11.
In the thermogram in differential scanning caiorimetry, the novel modification B has, in addition to an endothermic signal in the range from 230 C to 260 C (peak temperature 239-245 C), a weak thermal signal at 205 C (180 - 220 C) as a typical distinguishing feature compared with the modifications A or A' and C.
In the FT-IR spectrum (KBr pellet - transmission method), the novel modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 3137 cm" [cf. Figure 1), which is not to be observed in the corresponding spectra of the modifications A and B.
In the FT Raman spectrum (powder - reflection method 180 ), the novel modification B
differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm"
and 1086 cm" [cf. Figure 2], which are not present in the Raman spectra of the modifications A and C. In the range 3400-300 cm-', inter alia the following bands are obtained for the modification B: 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm''. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
The novel modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A, 2.83 A [cf. Table 11.
In the thermogram in differential scanning caiorimetry, the novel modification B has, in addition to an endothermic signal in the range from 230 C to 260 C (peak temperature 239-245 C), a weak thermal signal at 205 C (180 - 220 C) as a typical distinguishing feature compared with the modifications A or A' and C.
In the FT-IR spectrum (KBr pellet - transmission method), the novel modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 3137 cm" [cf. Figure 1), which is not to be observed in the corresponding spectra of the modifications A and B.
-5-In the range 4000-600 cm", inter alia the following bands are obtained for the novel modification C: 3396, 3287, 3137, 1657, 1631, 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm". For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR
spectra.
In the FT Raman spectrum (powder - reflection method 180 ), the modification C
differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm" and 1602 cm-' [cf.
Figure 2], which are not present in the Raman spectra of the modifications A
and B. In the range 3400-300 cm", inter alia the following bands are obtained for the modification C:
3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm". For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT
Raman spectra.
The novel modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A[cf.
Table 1]. In the thermogram in differential scanning calorimetry, the modification C has, in addition to an endothermic signal in the range of 230 C to 260 C (peak temperature 239-245 C), a very broad, weak, exothermic signal in the region of 180 C compared with the modifications A or A' and B.
Table 1: Characterization of the modifications A. B and C (X-ray gowder pattems):
Modification A: Modification'B: Modification C:
d~,.1 Intensi d~] Intensi 1ntensi 10.9 weak 11.0 medium 9.0 medium 10.5 medium 8.3 medium 7.0 weak
spectra.
In the FT Raman spectrum (powder - reflection method 180 ), the modification C
differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm" and 1602 cm-' [cf.
Figure 2], which are not present in the Raman spectra of the modifications A
and B. In the range 3400-300 cm", inter alia the following bands are obtained for the modification C:
3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm". For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT
Raman spectra.
The novel modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A[cf.
Table 1]. In the thermogram in differential scanning calorimetry, the modification C has, in addition to an endothermic signal in the range of 230 C to 260 C (peak temperature 239-245 C), a very broad, weak, exothermic signal in the region of 180 C compared with the modifications A or A' and B.
Table 1: Characterization of the modifications A. B and C (X-ray gowder pattems):
Modification A: Modification'B: Modification C:
d~,.1 Intensi d~] Intensi 1ntensi 10.9 weak 11.0 medium 9.0 medium 10.5 medium 8.3 medium 7.0 weak
6.6 w a 8.1 very weak 5.49 weak 5.63 weak 5.68 ve w ak 5.11 ve weak 5.25 weak 5.18 verv stronq 4.80 weak m dium 5.11 weak 4.73 strona 5.14 4.94 weak 4.88 medium 4.65 ve stron 4.84 very stron 4.80 stron 4.47 very weak 4.55 s ro 4.71 very weak 4.19 ve weak 4.42 ve weak 4.61 weak 4.11 very weak 4.34 medium 4.45 weak 3.98 very weak 4.23 ve weak 4.42 strona 3.83 very weak 4.16 weak 4.33 very strona 3.75 stron 4.07 medium 4.19 medium 3.73 weak 4.01 weak 4.12 s ron .54 medium 3.68 ve weak 4.09 weak 3.50 weak 3.64 very weak 3.99 vgrv weak 3.42 strona 3.60 weak 3.95 very weak 3.25 medium 3.56 weak 3.84 weak 2.88 ve weak 3.51 medium 3.81 medium 2.80 very weak 3.48 medium 3.65 weak 2.74 ve weak 3.38 very weak 3.61 very weak 2.67 very weak 3.25 strona 3.58 ve weak 2.64 weak 3.19 medium 3.54 weak 3.15 medium 3.50 medium 3.11 weak 3.47 ve weak 3.07 medium 3.41 medium 2.93 very weak 3.36 very stron 2.87 very weak 3.32 stron 2.81 medium 3.28 medium 2.76 weak 3.24 medium 2.73 ve weak 3.10 weak 2.68 weak 3.07 weak 2.62 very weak 3.05 medium 2.53 weak 2.93 weak 2.43 weak 2.88 weak 2.40 ve weak 2.87 very weak 2.83 medium 2.66 weak 2.63 very weak 2.55 weak 2.50 weak 2.46 weak 2.44 weak 2.37 weak
-7-Single crystal X-ray anaiysis:
Crystal quality and unit cell of modifications A, B, and C were verified by Weissenberg and precession photographs. The intensities were measured on a four-axis Nonius diffractometer. The structures were solved with the SHELXS-97 and refined with the SHELXL-97 software.
Modification A
Space group: Pna2, - orthorhombic Cell dimensions:
a = 24.756 (5)A b = 23.069 (4)P. c = 5.386 (1)A
v= 3075.9 A3 Z= 12 - Dx = 1.543 gcm-3 v per formula: Vz = 256.3 A3 9011 unique reflections; 2479 thereof significant with I > 20 (I). 557 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 3.65% (wR2 for all 9011 reflections: 11.34%).
Modification B
Space group: P -1 -triclinic Cell dimensions:
a = 5.326(1) A b = 11.976(2) A c = 17.355(3) A
a = 107.22(3) (3 = 92.17(3) y = 102.11(3) v= 1027.9 A3 Z= 4 Dx = 1.539 gcm-3 v per formula VZ = 257.0 A3 4934 unique reflections; 834 thereof significant with I > 2a (I). 232 parameters refined.
Crystal quality and unit cell of modifications A, B, and C were verified by Weissenberg and precession photographs. The intensities were measured on a four-axis Nonius diffractometer. The structures were solved with the SHELXS-97 and refined with the SHELXL-97 software.
Modification A
Space group: Pna2, - orthorhombic Cell dimensions:
a = 24.756 (5)A b = 23.069 (4)P. c = 5.386 (1)A
v= 3075.9 A3 Z= 12 - Dx = 1.543 gcm-3 v per formula: Vz = 256.3 A3 9011 unique reflections; 2479 thereof significant with I > 20 (I). 557 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 3.65% (wR2 for all 9011 reflections: 11.34%).
Modification B
Space group: P -1 -triclinic Cell dimensions:
a = 5.326(1) A b = 11.976(2) A c = 17.355(3) A
a = 107.22(3) (3 = 92.17(3) y = 102.11(3) v= 1027.9 A3 Z= 4 Dx = 1.539 gcm-3 v per formula VZ = 257.0 A3 4934 unique reflections; 834 thereof significant with I > 2a (I). 232 parameters refined.
-8-of all H atoms found by difference Fourier maps and refined isotropically.
Position Reliability index R,: 4.20% (wR2 for all 4934 reflections: 7.93%).
Modification C
Space group: P21/C - monoclinic Cell dimensions:
a= 10.982(2) A b = 5.350(1) A c = 17.945(3) A
0 = 91.59(1) v= 1053.9 A3 Z= 4 Dx = 1.501 gcm'3 v per formula: VZ = 263.5 A3 3073 unique reflections; 1071 thereof significant with I > 20 (I). 187 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 5,02% (wR2 for all 3073 reflections: 14.55%).
Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.
The modifications B and C have significant advantages compared with the modification A or A'.
Thus, it was found, for example, that modification B has a substantially faster dissolution rate in water and gastric fluid than modification A or A'. Consequently, when modification B
is used therapeutically, a rapid onset of action is achieved, which is particularly advantageous, for example in an acute epilepsy attack.
The invention reiates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet -transmission method): band at 1678 cm''.
Position Reliability index R,: 4.20% (wR2 for all 4934 reflections: 7.93%).
Modification C
Space group: P21/C - monoclinic Cell dimensions:
a= 10.982(2) A b = 5.350(1) A c = 17.945(3) A
0 = 91.59(1) v= 1053.9 A3 Z= 4 Dx = 1.501 gcm'3 v per formula: VZ = 263.5 A3 3073 unique reflections; 1071 thereof significant with I > 20 (I). 187 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 5,02% (wR2 for all 3073 reflections: 14.55%).
Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.
The modifications B and C have significant advantages compared with the modification A or A'.
Thus, it was found, for example, that modification B has a substantially faster dissolution rate in water and gastric fluid than modification A or A'. Consequently, when modification B
is used therapeutically, a rapid onset of action is achieved, which is particularly advantageous, for example in an acute epilepsy attack.
The invention reiates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet -transmission method): band at 1678 cm''.
-9- -The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.8a A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A and 2.83 A, determined by means of an X-ray powder pattern.
The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205 C (180-220 C) in addition to an endothermic signal in the range from 230 C to 260 C (peak temperature 239-245 C).
The invention furthermore relates to the crystal modification C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 3137 cm' '.
The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A, determined by means of an X-ray powder pattern.
The invention relates to modification C of 1-(2,6-difiuorobenzyl)-1 H-1,2,3-triazole-4-carbox-amide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-
The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205 C (180-220 C) in addition to an endothermic signal in the range from 230 C to 260 C (peak temperature 239-245 C).
The invention furthermore relates to the crystal modification C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 3137 cm' '.
The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, having characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A, determined by means of an X-ray powder pattern.
The invention relates to modification C of 1-(2,6-difiuorobenzyl)-1 H-1,2,3-triazole-4-carbox-amide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-
-10- _ carboxamide, having in the thermogram in differential scanning calorimetry a very broad weak exothermic signal in the region of 180 C, in addition to an endothermic signal in the range from 230 C-260 C (peak temperature 239-245 C).
The invention relates to the essentially pure forms of the modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The term "essentially pure form" means purity of >95%, in particular >98%, primarily >99%, based on the modifications B and C.
The invention relates to pharmaceutical preparations comprising the modifications B and C
of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof. The invention relates to the use of the modifications B and C of 1(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.
The novel modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for example oral, or parenteral administration. Furthermore, the novel modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions.
The pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations comprise from about 0.1 % to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.
The invention also relates to the use of the modifications B and C of 1-(2,6-difluorobenzyl)-
The invention relates to the essentially pure forms of the modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The term "essentially pure form" means purity of >95%, in particular >98%, primarily >99%, based on the modifications B and C.
The invention relates to pharmaceutical preparations comprising the modifications B and C
of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof. The invention relates to the use of the modifications B and C of 1(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.
The novel modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for example oral, or parenteral administration. Furthermore, the novel modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions.
The pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations comprise from about 0.1 % to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.
The invention also relates to the use of the modifications B and C of 1-(2,6-difluorobenzyl)-
-11- _ 1 H-1,2,3-triazole-4-carboxamide as a drug, preferably in the form of pharmaceutical preparations. The dosage may depend on various factors, such as method of administration, species, age and/or individual condition. The doses to be administered daily are between about 0.25 and about 10 mg/kg in the case of oral administration, and preferably between about 20 mg and about 500 mg for warm-blooded species having a body weight of about 70 kg.
The preparation of the modifications B and C is carried out, for example, as described in the embodiments below.
Example 1: Modification B
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (18.29 kg) is dissolved in formic acid (89.3 kg) at 58-63 C while stirring. The solution is discharged in the course of about 30 minutes onto stirred methanol (105.5 1) at 20 C to 0 C, after which washing with formic acid (6.1 kg) is carried out. A suspension forms. The product is isolated immediately by filtration and washed with cold methanol (150 I, about 4 C). By drying in vacuo at about 60 C, the product is obtained as modification B in a yield of about 94%.
Example 2: Modification C
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (15.0 g) is dissolved in acetic acid (120 ml) at about 90 C while stining. The solution is cooled to 20 C in the course of about 8 minutes, a suspension forming. The product is immediately isolated by filtration, washed with toluene (120 ml) and dried in vacuo at about 60 C. 10.1 g of the product are obtained as modification C. Yield 67.3%.
Formulation Example 1:
Film-coated tablets each containing, for example, 100, 200 or 400 mg of the modification B
.12-or C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide with the following composition per dosage unit:
Core material mg mg mg Active ingredient 100.00 200.00 400.00 = Anhydrous, colloidal silica 0.88 1.75 3.5 Microcrystalline cellulose 36.62 73.25 146.50 Hydroxypropylmethyl- 5.00 10.00 20.00 ceilulose Lactose 20.00 40.00 80.00 Magnesium stearate 2.00 4.00 8.00 Maize starch 10.00 20.00 40.00 Sodium carboxymethyl- 5.00 10.00 20.00 cellulose Sodium laurylsulfate 0.50 1.00 2.00 Film coat mg mg mg Hydroxypropylmethyl- 3.22 6.43 12.87 cellulose Red iron oxide 0.04 0.09 0.18 Palyethylene glycol 8000, 0.58 1.16 2.32 flakes Talc 2.33 4.66 9.31 Titanium dioxide 0.83 1.66 3.32 The active ingredient is granulated with demineralized water. Milled lactose, maize starch, TM
Avicei PH 102, cellulose-HP-M-603 and sodium iaurylsulfate are added to the above mixture and granulated with demineralized water.
The moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.
The tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.
Description of the Fictures Figure 1 shows the FT-IR spectra of the KBr pellets of crystal modifications A, B and C.
Figure 2 shows the FT-Raman spectra of the powder of modifications A, B and C.
In both Figures, the modification A is denoted by the symbol *, the modification B by the symbol ** and the modification C by the symbol ***.
The preparation of the modifications B and C is carried out, for example, as described in the embodiments below.
Example 1: Modification B
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (18.29 kg) is dissolved in formic acid (89.3 kg) at 58-63 C while stirring. The solution is discharged in the course of about 30 minutes onto stirred methanol (105.5 1) at 20 C to 0 C, after which washing with formic acid (6.1 kg) is carried out. A suspension forms. The product is isolated immediately by filtration and washed with cold methanol (150 I, about 4 C). By drying in vacuo at about 60 C, the product is obtained as modification B in a yield of about 94%.
Example 2: Modification C
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (15.0 g) is dissolved in acetic acid (120 ml) at about 90 C while stining. The solution is cooled to 20 C in the course of about 8 minutes, a suspension forming. The product is immediately isolated by filtration, washed with toluene (120 ml) and dried in vacuo at about 60 C. 10.1 g of the product are obtained as modification C. Yield 67.3%.
Formulation Example 1:
Film-coated tablets each containing, for example, 100, 200 or 400 mg of the modification B
.12-or C of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide with the following composition per dosage unit:
Core material mg mg mg Active ingredient 100.00 200.00 400.00 = Anhydrous, colloidal silica 0.88 1.75 3.5 Microcrystalline cellulose 36.62 73.25 146.50 Hydroxypropylmethyl- 5.00 10.00 20.00 ceilulose Lactose 20.00 40.00 80.00 Magnesium stearate 2.00 4.00 8.00 Maize starch 10.00 20.00 40.00 Sodium carboxymethyl- 5.00 10.00 20.00 cellulose Sodium laurylsulfate 0.50 1.00 2.00 Film coat mg mg mg Hydroxypropylmethyl- 3.22 6.43 12.87 cellulose Red iron oxide 0.04 0.09 0.18 Palyethylene glycol 8000, 0.58 1.16 2.32 flakes Talc 2.33 4.66 9.31 Titanium dioxide 0.83 1.66 3.32 The active ingredient is granulated with demineralized water. Milled lactose, maize starch, TM
Avicei PH 102, cellulose-HP-M-603 and sodium iaurylsulfate are added to the above mixture and granulated with demineralized water.
The moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.
The tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.
Description of the Fictures Figure 1 shows the FT-IR spectra of the KBr pellets of crystal modifications A, B and C.
Figure 2 shows the FT-Raman spectra of the powder of modifications A, B and C.
In both Figures, the modification A is denoted by the symbol *, the modification B by the symbol ** and the modification C by the symbol ***.
Claims (12)
1. A crystal modification B of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula having characteristic lines with interplanar spacings (d values) of 11.0 .ANG., 8.3 .ANG., 5.18 .ANG., 4.88 .ANG., 4.80 .ANG., 4.42 .ANG., 4.33 .ANG., 4.19 .ANG., 4.12 .ANG., 3.81 .ANG., 3.50 .ANG., 3.41 .ANG., 3.36 .ANG., 3.32 .ANG., 3.28 .ANG., 3.24 .ANG., 3.05 .ANG. and 2.83 .ANG., determined by means of an X-ray powder pattern.
2. A crystal modification according to claim 1, which has an X-ray powder pattern having the following characteristic lines with interplanar spacings (d values) of 11.0 .ANG. (medium), 8.3 .ANG.
(medium), 8.1 .ANG. (very weak), 5.68 .ANG. (very weak), 5.18 .ANG. (very strong), 5.11 .ANG. (weak), 4.88 .ANG. (medium), 4.80 .ANG. (strong), 4.71 .ANG. (very weak), 4.61 .ANG.
(weak), 4.45 .ANG. (weak), 4.42 .ANG.
(strong), 4.33 .ANG. (very strong), 4.19 .ANG. (medium), 4.12 .ANG. (strong), 4.09 .ANG. (weak), 3.99 .ANG. (very weak), 3.95 .ANG. (very weak), 3.84 .ANG. (weak), 3.81 .ANG. (medium), 3.65 .ANG. (weak), 3.61 .ANG. (very weak), 3.58 .ANG. (very weak), 3.54 .ANG. (weak), 3.50 .ANG. (medium), 3.47 .ANG. (very weak), 3.41 .ANG.
(medium), 3.36 .ANG. (very strong), 3.32 .ANG. (strong), 3.28 .ANG. (medium), 3.24 .ANG. (medium), 3.10 .ANG.
(weak), 3.07 .ANG. (weak), 3.05 .ANG. (medium), 2.93 .ANG. (weak), 2.88 .ANG.
(weak), 2.87 .ANG. (very weak) 2.83 .ANG. (medium), 2.66 .ANG. (weak), 2.63 .ANG. (very weak), 2.55 .ANG.
(weak), 2.50 .ANG. (weak), 2.46 .ANG.
(weak), 2.44 .ANG. (weak), 2.37 .ANG. (weak), 2.35 .ANG. (weak).
(medium), 8.1 .ANG. (very weak), 5.68 .ANG. (very weak), 5.18 .ANG. (very strong), 5.11 .ANG. (weak), 4.88 .ANG. (medium), 4.80 .ANG. (strong), 4.71 .ANG. (very weak), 4.61 .ANG.
(weak), 4.45 .ANG. (weak), 4.42 .ANG.
(strong), 4.33 .ANG. (very strong), 4.19 .ANG. (medium), 4.12 .ANG. (strong), 4.09 .ANG. (weak), 3.99 .ANG. (very weak), 3.95 .ANG. (very weak), 3.84 .ANG. (weak), 3.81 .ANG. (medium), 3.65 .ANG. (weak), 3.61 .ANG. (very weak), 3.58 .ANG. (very weak), 3.54 .ANG. (weak), 3.50 .ANG. (medium), 3.47 .ANG. (very weak), 3.41 .ANG.
(medium), 3.36 .ANG. (very strong), 3.32 .ANG. (strong), 3.28 .ANG. (medium), 3.24 .ANG. (medium), 3.10 .ANG.
(weak), 3.07 .ANG. (weak), 3.05 .ANG. (medium), 2.93 .ANG. (weak), 2.88 .ANG.
(weak), 2.87 .ANG. (very weak) 2.83 .ANG. (medium), 2.66 .ANG. (weak), 2.63 .ANG. (very weak), 2.55 .ANG.
(weak), 2.50 .ANG. (weak), 2.46 .ANG.
(weak), 2.44 .ANG. (weak), 2.37 .ANG. (weak), 2.35 .ANG. (weak).
3. A crystal modification according to claim 1 or 2, having the following absorption in the FT-IR
spectrum (KBr pellet - transmission method): 1678 cm-1.
spectrum (KBr pellet - transmission method): 1678 cm-1.
4. A crystal modification according to claim 3, having the following absorptions in the FT-IR
spectrum (KBr pellet - transmission method): 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm -1.
spectrum (KBr pellet - transmission method): 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm -1.
5. A crystal modification according to any one of claims 1-4, having the following absorptions in the FT-Raman spectrum (powder - reflection method 180°): 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm-1.
6. A crystal modification B according to any one of claims 1-5, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205°C (180-220°C) in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239-245°C).
7. A crystal modification B according to any one of claims 1 to 6 having a purity in excess of 95%.
8. A pharmaceutical composition comprising the crystal modification B of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 8 for treatment of epilepsy or a subindication thereof.
10. Use of crystal modification B according to any one of claims 1 to 7 in preparation of a pharmaceutical composition for treatment of epilepsy or a subindication thereof.
11. Use of crystal modification B according to any one of claims 1 to 7 for treatment of epilepsy or a subindication thereof.
12. Crystal modification B according to any one of claims 1 to 7 for treatment of epilepsy or a subindication thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2614926A CA2614926C (en) | 1997-06-10 | 1998-06-08 | Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH140497 | 1997-06-10 | ||
| CH1404/97 | 1997-06-10 | ||
| PCT/EP1998/003428 WO1998056773A1 (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2614926A Division CA2614926C (en) | 1997-06-10 | 1998-06-08 | Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2256015A1 CA2256015A1 (en) | 1998-12-17 |
| CA2256015C true CA2256015C (en) | 2008-06-03 |
Family
ID=4209650
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2614926A Expired - Lifetime CA2614926C (en) | 1997-06-10 | 1998-06-08 | Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| CA002256013A Expired - Lifetime CA2256013C (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| CA002256015A Expired - Lifetime CA2256015C (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2614926A Expired - Lifetime CA2614926C (en) | 1997-06-10 | 1998-06-08 | Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| CA002256013A Expired - Lifetime CA2256013C (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US6740669B1 (en) |
| EP (2) | EP0994863B1 (en) |
| JP (2) | JP3672575B2 (en) |
| KR (2) | KR100409168B1 (en) |
| CN (3) | CN1298708C (en) |
| AR (4) | AR012945A1 (en) |
| AT (2) | ATE232852T1 (en) |
| AU (2) | AU725517B2 (en) |
| BR (2) | BR9804946A (en) |
| CA (3) | CA2614926C (en) |
| CO (2) | CO4940448A1 (en) |
| CY (1) | CY2007014I2 (en) |
| CZ (2) | CZ292481B6 (en) |
| DE (3) | DE69811500T2 (en) |
| DK (2) | DK0994863T3 (en) |
| ES (2) | ES2192779T3 (en) |
| FR (1) | FR07C0037I2 (en) |
| HK (3) | HK1028241A1 (en) |
| HU (2) | HU225153B1 (en) |
| ID (2) | ID21014A (en) |
| IL (2) | IL125733A (en) |
| LU (1) | LU91345I2 (en) |
| MY (2) | MY120156A (en) |
| NL (1) | NL300284I2 (en) |
| NO (2) | NO329314B1 (en) |
| NZ (2) | NZ331370A (en) |
| PE (2) | PE79799A1 (en) |
| PL (2) | PL191943B1 (en) |
| PT (1) | PT994864E (en) |
| RU (2) | RU2198167C2 (en) |
| SI (2) | SI0994863T1 (en) |
| SK (2) | SK283734B6 (en) |
| TR (2) | TR199801631T1 (en) |
| TW (2) | TW526195B (en) |
| UY (1) | UY25844A1 (en) |
| WO (2) | WO1998056773A1 (en) |
| ZA (2) | ZA984967B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW526195B (en) | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
| TW200404802A (en) * | 2002-05-31 | 2004-04-01 | Schering Corp | Xanthine phosphodiesterase V inhibitor polymorphs |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
| US20090069390A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched rufinamide |
| CA2736703A1 (en) | 2008-10-13 | 2010-04-22 | Cipla Limited | Process for the preparation of rufinamide |
| CN101768124B (en) * | 2008-12-30 | 2012-01-04 | 北京本草天源药物研究院 | Medicine crystal, preparation method and purpose thereof |
| IT1395736B1 (en) * | 2009-08-04 | 2012-10-19 | Dipharma Francis Srl | CRYSTALLINE FORMS OF RUFINAMIDE |
| RU2594155C2 (en) * | 2009-09-04 | 2016-08-10 | Тэктикал Терапеутикс, Инк | Novel compositions and methods of producing 5-amino- or substituted amino-1,2,3-triazoles and triazole-orotate compositions |
| US8884026B2 (en) | 2010-04-30 | 2014-11-11 | Laboratorios Lesvi, S.L. | Process for preparing rufinamide intermediate |
| EP2465853A1 (en) * | 2010-12-14 | 2012-06-20 | Laboratorios Lesvi, S.L. | Polymorph of rufinamide and process for obtaining it |
| ITMI20110718A1 (en) * | 2011-04-29 | 2012-10-30 | Dipharma Francis Srl | PROCEDURE FOR PURIFICATION OF RUFINAMIDE |
| WO2014013511A2 (en) * | 2012-07-20 | 2014-01-23 | Hetero Research Foundation | Rufinamide solid dispersion |
| WO2021099481A1 (en) | 2019-11-20 | 2021-05-27 | Medichem, S.A. | Solid composition containing rufinamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992378A (en) | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
| US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
| GB1511195A (en) | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4346097A (en) * | 1980-09-30 | 1982-08-24 | Warner-Lambert Company | Method for treating convulsions with pyrazole-4-carboxamide derivatives |
| FI834666A (en) | 1982-12-23 | 1984-06-24 | Ciba Geigy Ag | FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR. |
| US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
| US4511572A (en) * | 1983-03-18 | 1985-04-16 | The University Of Kentucky Research Foundation | Triazoline anticonvulsant drugs |
| PH22568A (en) | 1985-04-18 | 1988-10-17 | Ciba Geigy Ag | Fluorinated benzyl triazoles and pharmaceutical compositions containing the same |
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| JPH02214504A (en) | 1989-02-15 | 1990-08-27 | Nissan Chem Ind Ltd | Method for depositing crystal of compound having plural crystal forms |
| EP0484437A4 (en) | 1989-07-27 | 1994-06-01 | Searle & Co | Renal-selective prodrugs for the treatment of hypertension |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| EP0556393B1 (en) | 1990-11-06 | 2000-07-26 | Yamanouchi Pharmaceutical Co. Ltd. | Fused pyrazine derivative |
| JP2753911B2 (en) | 1991-12-06 | 1998-05-20 | キッセイ薬品工業株式会社 | Crystal polymorph of N-tert-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride and method for producing the same |
| DE4217952A1 (en) | 1992-05-30 | 1993-12-02 | Basf Ag | Quinoxaline-2,3 (1H, 4H) diones |
| US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| GB9419318D0 (en) | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
| DK0812320T3 (en) | 1995-02-22 | 2003-04-14 | Aventis Pharma Ltd | Amorphous pyrethanide, polymorphic forms thereof, process for their preparation and their use |
| EP0918758B1 (en) * | 1996-07-11 | 2002-05-02 | Novartis AG | Process for preparing 1-substituted 4-cyano-1,2,3-triazoles |
| TW526195B (en) * | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
-
1998
- 1998-06-04 TW TW087108858A patent/TW526195B/en not_active IP Right Cessation
- 1998-06-04 TW TW087108859A patent/TW403740B/en not_active IP Right Cessation
- 1998-06-08 CA CA2614926A patent/CA2614926C/en not_active Expired - Lifetime
- 1998-06-08 ES ES98934929T patent/ES2192779T3/en not_active Expired - Lifetime
- 1998-06-08 EP EP98934929A patent/EP0994863B1/en not_active Expired - Lifetime
- 1998-06-08 DE DE69811500T patent/DE69811500T2/en not_active Expired - Lifetime
- 1998-06-08 SI SI9830405T patent/SI0994863T1/en unknown
- 1998-06-08 RU RU99104300/04A patent/RU2198167C2/en active
- 1998-06-08 PL PL330764A patent/PL191943B1/en unknown
- 1998-06-08 TR TR1998/01631T patent/TR199801631T1/en unknown
- 1998-06-08 CZ CZ19982533A patent/CZ292481B6/en not_active IP Right Cessation
- 1998-06-08 JP JP53628998A patent/JP3672575B2/en not_active Expired - Lifetime
- 1998-06-08 CZ CZ19982534A patent/CZ292260B6/en not_active IP Right Cessation
- 1998-06-08 DK DK98934929T patent/DK0994863T3/en active
- 1998-06-08 AU AU84372/98A patent/AU725517B2/en not_active Expired
- 1998-06-08 NZ NZ331370A patent/NZ331370A/en not_active IP Right Cessation
- 1998-06-08 BR BR9804946A patent/BR9804946A/en not_active Application Discontinuation
- 1998-06-08 BR BR9804947A patent/BR9804947A/en not_active Application Discontinuation
- 1998-06-08 DE DE69813560T patent/DE69813560T2/en not_active Expired - Lifetime
- 1998-06-08 PE PE1998000478A patent/PE79799A1/en not_active IP Right Cessation
- 1998-06-08 AU AU84371/98A patent/AU725528B2/en not_active Expired
- 1998-06-08 ID IDW980066D patent/ID21014A/en unknown
- 1998-06-08 WO PCT/EP1998/003428 patent/WO1998056773A1/en active IP Right Grant
- 1998-06-08 DE DE122007000051C patent/DE122007000051I2/en active Active
- 1998-06-08 CA CA002256013A patent/CA2256013C/en not_active Expired - Lifetime
- 1998-06-08 IL IL12573398A patent/IL125733A/en active Protection Beyond IP Right Term
- 1998-06-08 CN CNB2004100473675A patent/CN1298708C/en not_active Expired - Lifetime
- 1998-06-08 KR KR10-1998-0708149A patent/KR100409168B1/en not_active IP Right Cessation
- 1998-06-08 KR KR10-1998-0708150A patent/KR100425656B1/en not_active IP Right Cessation
- 1998-06-08 PE PE1998000479A patent/PE80999A1/en not_active IP Right Cessation
- 1998-06-08 TR TR1998/01630T patent/TR199801630T1/en unknown
- 1998-06-08 CN CNB988056755A patent/CN1159300C/en not_active Expired - Lifetime
- 1998-06-08 SI SI9830450T patent/SI0994864T1/en unknown
- 1998-06-08 ID IDW980065D patent/ID27660A/en unknown
- 1998-06-08 WO PCT/EP1998/003427 patent/WO1998056772A1/en active IP Right Grant
- 1998-06-08 AT AT98934929T patent/ATE232852T1/en active
- 1998-06-08 SK SK1094-98A patent/SK283734B6/en not_active IP Right Cessation
- 1998-06-08 PL PL330798A patent/PL192114B1/en unknown
- 1998-06-08 JP JP53628898A patent/JP3672574B2/en not_active Expired - Lifetime
- 1998-06-08 PT PT98934930T patent/PT994864E/en unknown
- 1998-06-08 HU HU0002113A patent/HU225153B1/en unknown
- 1998-06-08 RU RU99104299/04A patent/RU2194041C2/en active
- 1998-06-08 HU HU0000798A patent/HU226107B1/en unknown
- 1998-06-08 DK DK98934930T patent/DK0994864T3/en active
- 1998-06-08 CA CA002256015A patent/CA2256015C/en not_active Expired - Lifetime
- 1998-06-08 AT AT98934930T patent/ATE237599T1/en active
- 1998-06-08 NZ NZ331371A patent/NZ331371A/en not_active IP Right Cessation
- 1998-06-08 CN CN988000113A patent/CN1132820C/en not_active Expired - Lifetime
- 1998-06-08 EP EP98934930A patent/EP0994864B1/en not_active Expired - Lifetime
- 1998-06-08 ES ES98934930T patent/ES2197485T3/en not_active Expired - Lifetime
- 1998-06-08 IL IL12573298A patent/IL125732A/en not_active IP Right Cessation
- 1998-06-08 US US09/125,329 patent/US6740669B1/en not_active Expired - Lifetime
- 1998-06-08 SK SK1093-98A patent/SK283685B6/en not_active IP Right Cessation
- 1998-06-09 ZA ZA984967A patent/ZA984967B/en unknown
- 1998-06-09 CO CO98032885A patent/CO4940448A1/en unknown
- 1998-06-09 AR ARP980102707A patent/AR012945A1/en not_active Application Discontinuation
- 1998-06-09 AR ARP980102708A patent/AR012946A1/en not_active Application Discontinuation
- 1998-06-09 ZA ZA984966A patent/ZA984966B/en unknown
- 1998-06-09 CO CO98032879A patent/CO4940452A1/en unknown
- 1998-06-09 MY MYPI98002570A patent/MY120156A/en unknown
- 1998-06-09 MY MYPI98002572A patent/MY125854A/en unknown
- 1998-08-11 NO NO19983666A patent/NO329314B1/en not_active IP Right Cessation
- 1998-08-11 NO NO19983667A patent/NO329315B1/en not_active IP Right Cessation
-
1999
- 1999-12-10 UY UY25844A patent/UY25844A1/en not_active Application Discontinuation
-
2000
- 2000-10-25 HK HK00106804A patent/HK1028241A1/en not_active IP Right Cessation
- 2000-10-25 HK HK00106807A patent/HK1028242A1/en not_active IP Right Cessation
- 2000-11-17 HK HK00107340A patent/HK1028031A1/en not_active IP Right Cessation
-
2001
- 2001-05-31 US US09/871,366 patent/US6455556B2/en not_active Expired - Lifetime
-
2002
- 2002-11-14 US US10/294,408 patent/US20030125568A1/en not_active Abandoned
-
2004
- 2004-02-26 US US10/787,528 patent/US20040167186A1/en not_active Abandoned
-
2006
- 2006-01-11 US US11/329,945 patent/US7750028B2/en not_active Expired - Fee Related
-
2007
- 2007-05-17 AR ARP070102132A patent/AR061005A2/en not_active Application Discontinuation
- 2007-05-17 AR ARP070102131A patent/AR061004A2/en unknown
- 2007-07-03 NL NL300284C patent/NL300284I2/en unknown
- 2007-07-04 LU LU91345C patent/LU91345I2/en unknown
- 2007-07-06 FR FR07C0037C patent/FR07C0037I2/fr active Active
- 2007-07-13 CY CY200700014C patent/CY2007014I2/en unknown
-
2010
- 2010-04-26 US US12/767,003 patent/US8076362B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060116520A1 (en) | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide | |
| MXPA98006950A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic | |
| MXPA98006951A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180608 |